Literature DB >> 23137947

The consequences of different definitions for recurrence of Dupuytren's disease.

Hester J Kan1, Frank W Verrijp, Bionka M A Huisstede, Steven E R Hovius, Christianne A van Nieuwenhoven, Ruud W Selles.   

Abstract

BACKGROUND: Recurrence rates are important in the evaluation of the effectiveness of treatment for Dupuytren's disease (DD). In the literature, recurrence rates vary between 0% and 100%. The definition of recurrence of DD after treatment is inconsistently used. The aim of this study is to review all definitions of recurrence after treatment of DD and to evaluate the impact of using these definitions on a single cohort of patients treated for DD.
METHODS: A literature search was performed in PubMed and Embase to identify studies. Titles and abstracts were analysed to collect all articles that described recurrence rates or definitions of recurrence. Two independent reviewers selected relevant studies and extracted data. The different definitions of recurrence were applied on our data set of 66 patients.
RESULTS: Of the 113 articles reporting recurrent rates of DD, 56 (49%) presented a definition of recurrence. We could categorise the definitions into three groups. By applying the different definition on our data set of a randomised controlled trial, the recurrence rates ranged from 2% to 86%.
CONCLUSIONS: In the literature, different definitions of recurrence of DD are used and many authors failed to define recurrence. This study shows that the wide range of reported recurrence rates may largely be contributed by inconsistency in recurrence definitions. As a result, it is difficult or even impossible to compare recurrence rates between different treatments reported in the literature. The study indicates that consensus on a recurrence definition is needed.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 23137947     DOI: 10.1016/j.bjps.2012.08.019

Source DB:  PubMed          Journal:  J Plast Reconstr Aesthet Surg        ISSN: 1748-6815            Impact factor:   2.740


  11 in total

1.  Dupuytren Disease Management Trends: A Survey of Hand Surgeons.

Authors:  Logan Carr; Brett Michelotti; Morgan Brgoch; Randy Hauck; John Ingraham
Journal:  Hand (N Y)       Date:  2018-07-25

2.  Factors influencing recurrence and progression of Dupuytren's disease treated by Collagenase Clostridium histolitycum.

Authors:  Clarisa Simón-Pérez; Julian Alía-Ortega; Belen García-Medrano; Jose Ignacio Rodríguez-Mateos; Maria Brotat-Rodríguez; Hector Aguado-Hernandez; Miguel Angel Martín-Ferrero
Journal:  Int Orthop       Date:  2017-11-23       Impact factor: 3.075

3.  WT1 expression is increased in primary fibroblasts derived from Dupuytren's disease tissues.

Authors:  Justin Crawford; Christina Raykha; Daevina Charles; Bing Siang Gan; David B O'Gorman
Journal:  J Cell Commun Signal       Date:  2015-06-30       Impact factor: 5.782

4.  Clinical and morphological outcomes after percutaneous needle fasciotomy in Dupuytren's disease according to the contracture severity.

Authors:  Cristian Trâmbiţaş; Alina Dia Trâmbiţaş-Miron; Andrei Marian Feier; Octav Marius Russu; Dorin Constantin Dorobanţu; Klara Brînzaniuc
Journal:  Rom J Morphol Embryol       Date:  2021 Jul-Sep       Impact factor: 0.833

5.  Recurrence of Dupuytren's contracture: A consensus-based definition.

Authors:  Hester J Kan; Frank W Verrijp; Steven E R Hovius; Christianne A van Nieuwenhoven; Ruud W Selles
Journal:  PLoS One       Date:  2017-05-15       Impact factor: 3.240

6.  Multiple Recurrences in Aggressive Forms of Dupuytren's Disease-Can Patients Benefit from Repeated Selective Fasciectomy?

Authors:  Sören Könneker; G Felix Broelsch; Nicco Krezdorn; Khaled Dastagir; Jörn W Kuhbier; Felix J Paprottka; Peter M Vogt
Journal:  Plast Reconstr Surg Glob Open       Date:  2017-02-23

7.  3-Dimensional fasciectomy: A highly efficacious common ground approach to Dupuytren's surgery.

Authors:  Benjamin H Miranda; Charlotte Elliott; Christopher C Kearsey; David N Haughton; Mark R Webb; Ian Harvey; Fahmy S Fahmy
Journal:  Arch Plast Surg       Date:  2018-11-15

8.  Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren's disease, with an embedded dose response study.

Authors:  Jagdeep Nanchahal; Catherine Ball; Jennifer Swettenham; Susan Dutton; Vicki Barber; Joanna Black; Bethan Copsey; Melina Dritsaki; Peter Taylor; Alastair Gray; Marc Feldmann; Sarah Lamb
Journal:  Wellcome Open Res       Date:  2017-06-06

9.  A Weighted Genetic Risk Score Predicts Surgical Recurrence Independent of High-Risk Clinical Features in Dupuytren's Disease.

Authors:  Sophie A Riesmeijer; Oliver W G Manley; Michael Ng; Ilja M Nolte; Dieuwke C Broekstra; Paul M N Werker; Dominic Furniss
Journal:  Plast Reconstr Surg       Date:  2019-02       Impact factor: 4.730

Review 10.  Needle Fasciotomy or Collagenase Injection in the Treatment of Dupuytren's Contracture: A Retrospective Study.

Authors:  Islam Abdelrahman; Moustafa Elmasry; Ingrid Steinvall; Christina Turesson; Folke Sjöberg; Thomas Hansson
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.